# CapsoVision, Inc (CV) · Edgar & Edgarette company card

> CapsoVision (CV) grew revenue 15.3% in FY2025 to $14 million, operating margin -188% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 73.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1378325 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/CV) · [JSON](https://www.pops4.com/boards/company/CV.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $14M |
| Revenue growth, 1 year | 15.3% |
| Revenue growth per year | — |
| Operating margin | -188.3% (prior year -169.4%) |
| Net margin | -186.8% |
| Operating cash flow | −$23M |
| Capital spending | $90,000 |
| Free cash flow | −$23M |
| Cash | — |
| Long-term debt | — |
| Total assets | $18M |
| Total equity | $13M |
| Equity ÷ assets | 73.0% |
| Return on equity | -190.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -30.12 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -3.48 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -188.3% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $13.6M (FY2025). Experience: revenue up 15.3% on the year; operating margin -188.3%, down from -169.4%. Soundness: equity 73.0% of assets, return on equity -190.9%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $11.5M and $20.6M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin -188.3% against a 7.5% median; growth 15.3% against 8.3%.

Range logged 2026-09-21, receipt ef8ebb0cc98b5419, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-07-02 ([filing](https://www.sec.gov/Archives/edgar/data/1378325/000137832526000026/0001378325-26-000026-index.htm))

## Recent filings

- 8-K · filed 2026-09-28 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1378325/000137832526000045/0001378325-26-000045-index.htm)
- 8-K · filed 2026-09-18 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1378325/000137832526000043/0001378325-26-000043-index.htm)
- 8-K · filed 2026-08-18 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1378325/000137832526000039/0001378325-26-000039-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1378325/000137832526000036/0001378325-26-000036-index.htm)
- 8-K · filed 2026-08-13 · 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/0001378325-26-000035-index.htm)
- 8-K · filed 2026-07-02 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1378325/000137832526000026/0001378325-26-000026-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001378325.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1378325

## Cite

POPS4, Edgar & Edgarette: CapsoVision, Inc (CV) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/CV. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.